You are here

  • Home
  • Archive
  • Volume 78, Issue 5
  • Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Citation Tools

Article menu
Download PDFPDF
Sjögren’s syndrome
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Dörner T, Posch MG, Li Y, et al
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
Annals of the Rheumatic Diseases 2019;78:641-647.